Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2011-11-16 Investor Presentation
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
8-K Filing
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated November 16, 2011. It announces an updated Investor Presentation by Insmed Incorporated, which will be presented at a healthcare conference and made available on the company's website. The document includes no actual financial statements or detailed financial analysis but rather provides information about the presentation event and the availability of the presentation materials as an exhibit. The document length is 2977 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is an announcement of a report (the Investor Presentation) rather than the report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2011-11-16 English
8-K Filing
Call Transcript Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2011. It specifically mentions that on November 8, 2011, the company held a conference call to discuss financial results for the three and nine months ended September 30, 2011. The document includes a transcript of this conference call as Exhibit 99.1. The text explicitly states that the transcript is attached and incorporated by reference. The content and context clearly indicate this is a full text transcript of a company conference call, which matches the definition of a Call Transcript (CT). The document length is 3767 characters, which is relatively short but contains the transcript or a reference to it. Since the transcript is attached as an exhibit and the main purpose of the filing is to provide this transcript, the classification as Call Transcript (CT) is appropriate with high confidence.
2011-11-09 English
10-Q Filing
Interim / Quarterly Report Q3 2011
2011-11-09 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2011. It reports the issuance of a press release regarding financial results for the three and nine months ended September 30, 2011. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is not deemed "filed" for certain regulatory purposes. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of financial results via a press release. Given the document length is only 2628 characters and it primarily serves as a notification of the press release, it fits the criteria of a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR).
2011-11-08 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a clinical hold notification from the FDA regarding a phase 3 clinical trial, and it references an attached press release. The document is relatively short (2986 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements, management discussion, or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2011-10-14 English
8-K Filing
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a clinical hold notification from the FDA regarding the company's phase 3 clinical trials, which is an event update rather than a financial report or detailed management discussion. The document includes a press release as an exhibit and is signed by the CFO. The length is 3216 characters, which is relatively short and focused on a specific event. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain financial statements or detailed financial analysis. It is not an Annual Report, Earnings Release, or any other specific report type. Therefore, the correct classification is Regulatory Filings (RNS).
2011-10-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.